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Abstract
Introduction: Intervertebral disc (IVD) degeneration is characterized by extracellular matrix breakdown and is
considered to be a primary cause of discogenic back pain. Although increases in pro-inflammatory cytokine levels
within degenerating discs are associated with discogenic back pain, the mechanisms leading to their
overproduction have not yet been elucidated. As fragmentation of matrix components occurs during IVD
degeneration, we assessed the potential involvement of hyaluronic acid fragments (fHAs) in the induction of
inflammatory and catabolic mediators.
Methods: Human IVD cells isolated from patient biopsies were stimulated with fHAs (6 to 12 disaccharides) and
their effect on cytokine and matrix degrading enzyme production was assessed using quantitative real-time
polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA). The involvement of specific
cell surface receptors and signal transduction pathways in mediating the effects of fHAs was tested using small
interfering RNA (siRNA) approaches and kinase inhibition assays.
Results: Treatment of IVD cells with fHAs significantly increased mRNA expression levels of interleukin (IL)-1b, IL-6,
IL-8, cyclooxygenase (COX)-2, matrix metalloproteinase (MMP)-1 and -13. The stimulatory effects of fHAs on IL-6
protein production were significantly impaired when added to IVD cells in combination with either Toll-like
receptor (TLR)-2 siRNA or a TLR2 neutralizing antibody. Furthermore, the ability of fHAs to enhance IL-6 and MMP-3
protein production was found to be dependent on the mitogen-activated protein (MAP) kinase signaling pathway.
Conclusions: These findings suggest that fHAs may have the potential to mediate IVD degeneration and
discogenic back pain through activation of the TLR2 signaling pathway in resident IVD cells.
Introduction
Intervertebral disc (IVD) degeneration is considered to
be a major contributory factor to the development of
discogenic low back pain (LBP), a prevalent and costly
musculoskeletal disorder [1,2]. Efforts to develop more
effective therapies to combat this condition are ham-
pered by the lack of information relating to the patho-
physiological mechanisms responsible for instigating
IVD degeneration and the ensuing LBP. There is, how-
ever, some evidence suggesting that elevated levels of var-
ious pro-inflammatory cytokines within degenerated IVDs
may play a decisive role in mediating pain sensation
[3-6]. Therefore, a better appreciation of the processes
governing cytokine production within degenerated IVDs
may help in the development of more effective treatment
strategies to combat discogenic LBP.
Breakdown of the IVD extracellular matrix (ECM) is
driven by a collection of proteolytic enzymes of which
the matrix metalloproteinases (MMPs) and aggreca-
nases (members of the ADAMTS (A Disintegrin And
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Metalloproteinase with Thrombospondin Motifs) family)
have been the most extensively studied [7-10]. These
have the potential to degrade numerous matrix compo-
nents as well as to give rise to a variety of reactive frag-
ment species, which themselves may further act to
stimulate and activate IVD cells. This is made evident by
findings from our own studies, and from others, where
proteolytic fragments of fibronectin and type II collagen
have been shown to induce MMP expression in human
IVD cells [11-14]. In addition to proteins and proteogly-
cans, numerous glycosaminoglycans (GAGs) also exist
within the IVD, and include hyaluronic acid (HA), chon-
droitin sulfate and keratan sulfate, although only HA
exists in the form of a free GAG [15]. Among these, HA
has received significant attention due to the stimulatory
nature of its degradation products on various cell types.
HA is a polymer composed of repeating disaccharide
units comprised of D-glucuronic acid and D-N-
acetylglucosamine. Whilst existing as a high molecular
weight (HMW) polymer (>106 kDa) under normal con-
ditions, HA can become degraded in response to var-
ious pathogenic events resulting in the generation of
low molecular weight (LMW) fragments (fHAs) [16].
This may be brought about through the actions of var-
ious enzymes, such as hyaluronidases [17], as well as
by exposure to non-enzymatic mediators, including
reactive oxygen species (ROS) [18]. More specifically,
pro-inflammatory agents, such as IL-1b, have been
shown to induce the release and fragmentation of HA
from cartilage explants [19]. This may be of particular
relevance to the development of degenerative disc dis-
ease, where reductions in GAG content together with
increases in IL-1b are wholly evident in degenerated
IVDs [20,21]. Although there is currently no evidence
confirming the presence of fHAs within disc tissue, it
may be reasonable to assume that the sequence of cata-
bolic and inflammatory events within the degenerating
disc could provide an environment conducive to the
production of fHAs. However, the potential involve-
ment of such fragments in the pathogenesis of IVD
degeneration has not yet been considered. Certainly,
fHAs have the capacity to invoke both an inflammatory
response as well as induce synthesis of tissue degrading
enzymes when added to chondrocytes in vitro [22-25].
These effects are mediated through HA cell surface
receptors CD44 and/or toll-like receptor (TLR)-4, with
subsequent activation of NF-B [24,25]. The receptor
for hyaluronan-mediated motility (RHAMM, CD168)
may also represent an additional means through which
fHAs could mediate their stimulatory effects [26].
However, no studies have yet sought to investigate the
influence of fHAs on the inflammatory and catabolic
response in human IVD cells, and to assess their possi-
ble mode of action.
In the current report, we have set out to investigate the
in vitro effects of fHAs on human IVD cells isolated from
the discs of patients undergoing spine surgery. Small
fHAs ranging in size from 12 to 24 mer were incubated
with IVD cells and their influence on inflammatory and
catabolic processes evaluated. Furthermore, studies were
conducted in an attempt to identify the signalling path-
ways responsible for mediating the effects of fHAs. Our
results clearly demonstrate that fHAs enhance both the
pro-inflammatory and catabolic response in IVD cells,
being mediated primarily through the TLR2 signaling
pathway. These findings may be considered of significant
clinical importance, based on the fact that increases in
pro-inflammatory cytokine and MMP production are
main features of IVD degeneration.
Materials and methods
Isolation and culture of IVD cells
Human IVD tissue was obtained from patients under-
going spinal surgery for symptomatic degenerative disc
disease, disc herniation or spinal trauma following
informed consent in accordance with the Ethics Com-
mittee of the Canton of Zurich (carried out at University
Hospital Balgrist, Zurich, Switzerland) (Table 1) and
Table 1 Details of patients used in the study.
Patient Pathology Severity Gradea Disc Level
1 DH 4 L4/5
2 SD 5 L4/5
3 DH 5 L4/5
4 DH 5 C5/6
5 DH 5 L5/S1
6 DH 4 L4/5
7 DH 3 L5/S1
8 DH 5 L5/S1
9 DH 4 L4/5
10 DH 4 L4/5
11 DH 5 L4/5
12 DH 4 L4/5
13 DH 3 L2/3
14 DH 4 L5/S1
15 DH 4 L5/S1
16 DH 5 L5/S1
17 DH 3 L5/S1
18 DH 5 L4/5
19 DH 4 L5/S1
20 DH 4 C6/7
21 DH 4 L4/5
22 DH 5 L5/S1
a The degree of IVD degeneration in patients was assessed prior to surgical
intervention by magnetic resonance imaging (MRI) using a 5-level grading
system based on Pfirrmann’s classification of disc degeneration.
C, cervical; DH, disc herniation; F, female; L, lumber; M, male; S, sacral; SD,
segment degeneration
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IVD cells isolated and cultured as previously described
[11]. Cells were used for experiments at passages 2 to 3.
Preparation of HA fragments
Hyaluronic acid oligomers of 6 to 12 disaccharide units
in length were prepared as previously described [27].
Ultrapure HMW HA (Healon 5), kindly provided by
Amo (Ettlingen, Germany), was dissolved at 5 mg/ml
in 0.3 M sodium phosphate buffer, pH 5.3, sonified and
subsequently enzymatically digested with 200 U/ml
bovine testis hyaluronidase (Sigma-Aldrich, Seelze,
Germany) for six hours at 37°C. The resulting
fragments were separated on a Bio Gel P10 column
(3.5 × 115 cm) (BioRad, Munich, Germany) and 3 ml
fractions collected. The concentration of HA in the
fractions was determined by measuring the absorbance
at 210 nm with reference to standards. The fractions
were tested for endotoxin contamination using the
Limulus Amebocyte Lysate (LAL)-assay kit (Lonza,
Verviers, Belgium) according to the manufacturer’s
instructions. In all cases, endotoxin levels were below
detection limits.
For determination of HA fragment size, fluorophore-
assisted carbohydrate electrophoresis (FACE) analysis of
7-amino-1,3-naphthalenedisulfonic acid (ANDS)-labeled
fragments was performed. Briefly, samples were dried
and resuspended in 5 µl 0.15 M ANDS (in 0.15% Acetic
Acid) and 5 µl 1 M NaCNBH4 (in DMSO) (both Sigma-
Aldrich). After 16 hours at 37°C the samples were dried
and resuspended in 20% glycerine. Samples were sepa-
rated on a 30% polyacrylamide gel at 15 mA. Bands
were visualized in the gel by UV illumination. The size
of the oligosaccharides in the fractions was determined
by comparing the bands with similarly labeled, commer-
cially available HA fragments of defined sizes (Sigma-
Aldrich) (Figure 1).
Figure 1 Preparation of fHAs. High molecular weight (HMW) hyaluronic acid (HA) was digested with bovine testis hyaluronidase. The resulting
fragments were separated on a Bio Gel P10 column. For determination of fragment size fluorophore-assisted carbohydrate electrophoresis
(FACE) analysis was performed. In this example, fractions 18, 23, 42, 48 and 64 derived from one HA-preparation were compared with a
commercially-available HA standard (Sigma-Aldrich). M, HA standard marker; ds, disaccharide units.
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Gene expression profile in IVD cells treated with fHAs
IVD cells (1 × 106) were cultured in 150 cm2 flasks and
starved in serum-free medium for 2 h prior to stimulation.
Cells were incubated in medium alone or medium supple-
mented with fHAs (5 or 20 µg/ml) for up to 18 hours.
Total RNA was isolated from IVD cells using the PureLink
RNA Mini kit (Life Technologies, Zug, Switzerland)
according to the manufacturer’s recommendation
(Life Technologies), then 1 μg total RNA was reverse-
transcribed using Superscript II (Life Technologies).
Quantification of mRNA expression was performed on the
StepOnePlus Real-Time PCR System (Life Technologies)
using the TaqMan Gene Expression Assays (Life Technol-
ogies) specific for IL-1b, IL-6, IL-8, TNF-a, MMP-1, -2, -3,
-9, -13, COX-2, ADAMTS4 and ADAMTS5 (Table 2).
Values were normalized to TATA-Box binding protein
(TBP) mRNA levels and presented as either 2-ΔCT or as
fold change as compared to untreated cells according to
the 2-ΔΔCT method where stated.
Stimulation of IL-6 production in IVD cells
IVD cells (1.3 x105) were cultured in 12-well plates and
starved in serum-free medium for 2 h prior to stimula-
tion. Cells were incubated in medium alone or medium
supplemented with fHAs (20 µg/ml), Pam3CysSerLys4
(Pam3CSK4) (25 ng/ml) (LabForce, Nunningen,
Switzerland), IL-1b (5 ng/ml) (Peprotech, London, UK) or
lipopolysaccharide (LPS) (25 ng/ml) (LuBioScience,
Luzern, Switzerland) for up to 18 hours. Culture superna-
tants were harvested for further analysis using a specific
IL-6 ELISA (BD Biosciences, Allschwil, Switzerland).
The effect of gene silencing on fHA-mediated IL-6
production in IVD cells
Specific knock down of TLR2, TLR4, CD44 and RHAMM
expression was performed with small interfering (si)RNA
oligos (Qiagen, Hombrechtikon, Switzerland). Human
IVD cells (1.3 × 105 cells) were transfected with 10 or 20
nM of siRNA specific for TLR2 (SI00050036), TLR4
(SI04951149), CD44 (SI00299705), or RHAMM (SI04
435347), or negative control siRNA (SI03650325) using
lipofectamine RNAiMAX (Life Technologies) in 12-well
plates. Following transfection, cells were incubated with
fresh growth medium (without antibiotics) and incubated
for 24 hours at 37°C, 5% CO2. Cells were then stimulated
with fHAs (20 μg/ml) for 18 hours and culture superna-
tants harvested for further analysis using a specific IL-6
ELISA (BD Biosciences).
The effect of TLR2 inhibition on fHA-mediated IL-6
production in IVD cells
IVD cells (1.3 × 105) were cultured in 12-well plates and
starved in serum-free medium for 2 h prior to stimulation.
Cells were then pre-incubated for one hour with either an
affinity purified polyclonal rat anti-human TLR2 neutraliz-
ing antibody (final concentration 5 µg/ml) (LabForce,
Switzerland) or an isotype matched IgG control (Lucerna-
Chem, Luzern, Switzerland). Cells were then stimulated
with fHAs (20 μg/ml) or Pam3CSK4 (25 ng/ml) for 18
hours and culture supernatants harvested for further ana-
lysis using a specific IL-6 ELISA (BD Biosciences).
The role of NF-B in fHA-dependent IVD cell activation
IVD cells (3 × 105) were cultured in six-well plates and
starved in serum-free medium for 2 h prior to stimula-
tion. Cells were then treated for up to one hour with
either fHAs (20 μg/ml) or IL-1b (5 ng/ml). For the detec-
tion of NF-B (p65) by immunofluorescence, cells were
fixed with ice cold methanol (-20°C) for 10 minutes at
selected time points, blocked for 10 minutes with PBS
containing 1% BSA (Sigma) and 0.1% Triton-X100
(Sigma), and incubated with polyclonal rabbit anti-NF-
B (p65) (Santa Cruz Biotechnologies, Heidelberg,
Germany) (1:200) for one hour at room temperature. NF-
B (p65) was detected using goat anti-rabbit Cy2 (Jackson
ImmunoResearch, Newmarket, Suffolk, UK) (1:200) and
visualized by fluorescence microscopy. For Western blot
analysis, cells were first washed with buffer containing 10
mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 1 mM
PMSF, 5 mM DTT with freshly added protease inhibitor
cocktail (Sigma-Aldrich) and then lysed with 0.1% NP-40
for five minutes on ice. Nuclear pellets were harvested
after centrifugation at 10,000 rpm for 5 minutes at 4°C,
and lysed for 20 minutes in buffer containing 20 mM
HEPES (pH 7.9), 1.5 mM MgCl2, 420 mM NaCl, 25% gly-
cerol, 1 mM PMSF and 5 mM DTT. Protein concentra-
tions were determined using the Bradford Assay (BioRad)
and equal amounts loaded onto 12% SDS-PAGE gels. Pro-
tein was subsequently electroblotted onto PVDF mem-
branes and incubated with nonfat dry milk (5%), 50 mM
Table 2 TaqMan gene expression assays used for
qRT-PCR.
Target gene Assay ID
TATA box binding protein (TBP) Hs00427620_m1
Interleukin 1 b (IL-1b) Hs00174097_m1
Interleukin 6 (IL-6) Hs00174131_m1
Interleukin 8 (IL-8) Hs00174103_m1
Tumor Necrosis Factor a (TNFa) Hs00174128_m1
Matrix metalloproteinase 1 (MMP-1) Hs00233958_m1
Matrix metalloproteinase 2 (MMP-2) Hs01548724_m1
Matrix metalloproteinase 3 (MMP-3) Hs00968308_m1
Matrix metalloproteinase 9 (MMP-9) Hs00957555_m1
Matrix metalloproteinase 13 (MMP-13) Hs00233992_m1
Cyclooxygenase 2 (COX-2) Hs00153133_m1
Aggrecanase 1 (ADAMTS4, AD4) Hs00943031_g1
Aggrecanase 2 (ADAMTS5, AD5) Hs00199841_m1
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Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20 (TBST)
for one hour at room temperature. Membranes were then
incubated for 2 hours at room temperature with either
anti- NF-B (p65) (1:200) or anti-PARP1 (1:1,000) (both
from LabForce, Switzerland). After washing in TBST three
times for five minutes each, membranes were incubated
with an appropriate HRP-conjugated secondary antibody
for one hour at room temperature. Following a further
washing step, peroxidase activity was detected using
SuperSignal West Dura Chemiluminescent Substrate
(Thermo Scientific, Lausanne, Switzerland). NF-B (p65)
binding activity was measured in nuclear extracts from
IVD cells using the NF-B (p65) Transcription Factor
Assay according to the manufacturer’s recommendations
(Cayman, Tallinn, Estonia). All absorbance measurements
were carried out at 655 nm.
Role of MAP kinases in mediating the effects of fHAs in
IVD cells
Cultured IVD cells were treated for 15 minutes with
fHAs (20 μg/ml), IL-1b (5 ng/ml), LPS (25 ng/ml) or
left untreated and whole protein cell extracts isolated
following lysis in buffer containing 50 mM HEPES (pH
7.5), 450 mM NaCl, 15% glycerol, 2 mM EDTA, 1 mM
PMSF and a freshly added protease inhibitor cocktail
(Sigma-Aldrich). Protein was harvested following centri-
fugation at 14,000 rpm for 30 minutes and equal
amounts loaded onto 12% SDS-PAGE gels and trans-
ferred to PVDF. Membranes were then incubated for
two hours with either rabbit anti-p38 (1:1,000), rabbit
anti-phospho-p38 (Thr180/Tyr182) (1:1,000), rabbit
anti-p44/44 (1:1,000), rabbit anti-phospho-p44/42
(1:1,000), rabbit anti-SAPK/JNK (1:1,000) or rabbit anti-
phospho-SAPK/JNK (Thr183/Tyr185) (1:200) (all from
Cell Signaling Technology, Allschwil, Switzerland) and
further analysed as described above. The functional role
of MAP kinases in mediating the effects of fHAs was
investigated using MAP kinase inhibitors. IVD cells
were treated with fHA (20 μg/ml) alone (Control) or in
combination with MAP kinase inhibitors (10 μM) speci-
fic for p38 (SB203580), ERK 1/2 (PD98059) or SAPK/
JNK (SP600125) and culture supernatants harvested for
further analysis using ELISAs specific for IL-6 (BD Bios-
ciences) or MMP-3 (R and D Systems, Abingdon, UK)
according to the manufacturer’s protocol.
Statistical analysis
All statistical analyses were carried out using SPSS19.0
(SPSS Inc., Chicago, IL, USA). Data were first assessed
for normality of distribution using the Kolmogorov-
Smirnov test. Parametric analysis of normally distributed
data was performed using the two-tailed unpaired Stu-
dent’s t-test or one-way analysis of variance (ANOVA)
followed by Tukey’s post-hoc tests for multiple group
comparisons. Non-parametric data were analyzed using
the Kruskal-Wallis one-way analysis of variance for mul-
tiple group comparisons followed by the Mann-Whitney
U test for comparisons between two groups. A P-value
of <0.05 was considered statistically significant. All data
were expressed as mean ± standard deviation (S.D.).
Results
Effect of fHAs on the expression of inflammatory and
catabolic genes in IVD cells
Initial experiments were undertaken in order to assess
the effects of fHAs on the expression of a range of
inflammatory and catabolic genes in cultured IVD cells.
Treatment of IVD cells was carried out for up to 18
hours using concentrations of fHAs based on previous
studies [24,28]. Stimulation of cells with fHAs at either
5 or 20 μg/ml resulted in significant alterations in sev-
eral of the genes analysed (Figure 2). The most notice-
able effects were observed in cells treated with the
higher dose of fHAs (20 μg/ml), where significant
increases in expression levels were measured for IL-1b
(P <0.01), IL-6 (P <0.05), IL-8 (P <0.01), MMP-1 (P
<0.01), MMP-13 (P <0.05) and COX-2 (P <0.01). All
subsequent experiments therefore involved the use of
fHAs at 20 μg/ml.
The stimulatory effect of fHAs on IVD cells is dependent
on functionally active TLR2
Of the genes identified as being regulated by fHAs, IL-6
was considered an appropriate candidate for further
investigations based on its roles as both a pro-inflamma-
tory cytokine and also as a mediator of pain [3].
Stimulation of IVD cells with fHAs induced a signifi-
cant increase in IL-6 protein production (3.5 ± 1.5 ng/ml;
P <0.01) as compared to untreated cells (Figure 3A), as
did other well-known instigators of IL-6 production,
including toll-like receptor activators Pam3CSK4 (6.0 ±
3 ng/ml) (Figure 3B) and LPS (10.8 ± 7.85 ng/ml)
(Figure 3C), as well as the pro-inflammatory cytokine
IL-1b (120 ± 36 ng/ml) (Figure 3D).
An siRNA approach was then used to target genes
encoding the cell surface receptors TLR2, TLR4, CD44
and RHAMM, with the aim of identifying potential recep-
tors involved in engaging fHAs. Knockdown efficiency
was confirmed in IVD cells after 24 hours using qRT-
PCR (Figure 4A). TLR2 and TLR4 were selected for
further evaluation of functional loss of receptor activity.
Confirmation of efficient and comparable TLR2 and
TLR4 loss-of-function was substantiated in siRNA-treated
cells through examination of their ability to express IL-6
following incubation with TLR ligands Pam3CSK4
(Figure 4B) and LPS (Figure 4C). fHA-dependent IL-6
production by IVD cells was also significantly reduced
following TLR2 loss-of-function (Figure 4D), although no
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significant reductions in IL-6 production were observed
in cells in which TLR4, CD44 or RHAMM had been
knocked down.
Further confirmation of TLR2’s involvement in the acti-
vation of IVD cells by fHAs was demonstrated in antibody-
mediated neutralization studies. Initial studies confirmed
the effectiveness of the polyclonal anti-TLR2 antibody to
neutralize TLR2 activity as demonstrated by its ability to
suppress Pam3CSK4-dependent IL-6 production as com-
pared to a non-specific IgG control antibody (Figure 5A).
Similarly, antibody-mediated TLR2 inactivation also signifi-
cantly reduced (P <0.05) the stimulatory effects of fHAs on
IL-6 production by IVD cells (Figure 5B).
The role of NF-B in fHA-mediated IVD activation
Activation of NF-B is considered to be a primary
means through which fHAs mediate their stimulatory
effects in chondrocytes [24,25]. We, therefore, carried
out a series of experiments to investigate whether fHAs
could also induce NF-B activation in human IVD cells.
We were unable to observe any evidence of NF-B
activation in IVD cells following stimulation with fHAs
(20 μg/ml). This was clearly demonstrated by the lack of
any increase in nuclear p65 as determined by both
immunofluorescence staining (Figure 6A) and also Wes-
tern blot analysis (Figure 6B) as compared to untreated
cells. Furthermore, nuclear extracts harvested from IVD
Figure 2 Gene expression profile in IVD cells treated with fHAs. Human IVD cells were incubated for 18 hours with hyaluronic acid
fragments (fHAs) at either 5 or 20 μg/ml (n = 4 to 6) and RNA harvested for analysis by qRT-PCR. Values were normalized to TATA-Box binding
protein (TBP) mRNA and expressed as 2-ΔCT. Statistical analysis was performed using the Kruskal-Wallis one-way analysis of variance for multiple
group comparisons followed by the Mann-Whitney U test for comparisons between two groups, * P <0.05, ** P <0.01 as compared to untreated
IVD cells. IL, interleukin; TNF, tumor necrosis factor; MMP, matrix metalloproteinase; COX, cyclooxygenase; ADAMTS, A Disintegrin And
Metalloproteinase with Thrombospondin Motifs.
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cells treated with fHAs demonstrated no significant
increase in NF-B (p65) DNA binding activity when
tested using a specific transcription factor assay (Figure
6C). This was in direct contrast to cells treated with IL-
1b, where obvious increases in nuclear p65 were evident
in all of the performed analyses.
Activation of IVD cells by fHAs is dependent on MAP
kinase signalling pathways
Based on the fact that TLR2 signalling also partly relies on
the MAP kinase pathway [29], we next investigated
whether fHAs had the capacity to activate various MAP
kinases in IVD cells. Western blot analysis revealed a
marked increase in the level of phosphorylated c-Jun-N-
terminal kinase/stress-activated protein kinase (JNK/
SAPK) (Figure 7A). In addition, we also saw a noticeable
increase in the level of phosphorylated extracellular signal-
regulated kinase (ERK) 1/2 (p44/p42) in cells treated with
fHAs (Figure 7B). However, by comparison, only marginal
increases in the level of p38 MAP kinase phosphorylation
were observed in response to fHAs (Figure 7C).
In order to further clarify the potential involvement of
MAP kinase activity in regulating fHA-dependent IVD
cell activation, we performed additional experiments uti-
lizing specific MAP kinase inhibitors. The stimulatory
effects of fHAs on IL-6 production by IVD cells were
significantly reduced following pre-exposure of the cells
to either ERK inhibitor PD98059 (P <0.05) or JNK inhi-
bitor SP600125 (P <0.01) (Figure 7D). The p38 MAP
kinase inhibitor, SB203580, had only a weak inhibitory
effect on fHA-dependent IL-6 production, which did not
reach statistical significance (P = 0.27). We also investi-
gated the ability of MAP kinase inhibitors to affect fHA-
induced MMP production in IVD cells. As with IL-6,
MMP-3 protein production was up-regulated by over
four-fold (P <0.01) in IVD cells treated with fHAs
(Figure 7E) and was significantly reduced following inhi-
bition of JNK activity (P <0.01).
Figure 3 Stimulation of IL-6 production in IVD cells. Human intervertebral disc (IVD) cells were incubated for 18 hours with either: hyaluronic
acid fragments (fHAs) (20 μg/ml) (n = 4) (A); Pam3CSK4 (25 ng/ml) (n = 4) (B); lipopolysaccharide (LPS) (25 ng/ml) (n = 5) (C); or interleukin (IL)-
1b (5 ng/ml) (n = 5) (D), and IL-6 protein levels determined in supernatants using a specific ELISA. In all cases, analyses were performed in
triplicate and values expressed as mean ± S.D. Statistical analysis was performed using the Student’s t-test, * P <0.05, ** P <0.01 as compared to
untreated IVD cells.
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Discussion
The primary source of discogenic back pain has been
debated over the years, although there is now a growing
body of evidence suggesting a close causal relationship
between pro-inflammatory cytokine expression and the
development of pain within the degenerated IVD
[3,10,30]. Certainly, pro-inflammatory mediators have
the capacity to provoke pain sensation [4-6], although it
remains unclear as to which processes are responsible
for initiating the ensuing cascade of cytokines in dis-
eased discs. Considering the fact that discogenic back
pain occurs primarily in degenerated discs, it is highly
likely that the processes governing disc degeneration
also play a role in instigating pro-inflammatory cytokine
production.
Degradation of the ECM through catabolic processes
can result in the generation of a variety of matrix pro-
tein fragments with the potential to influence cellular
behavior in numerous tissue types, usually with a detri-
mental outcome [9,11,12,31-33]. Furthermore, fragments
generated from HA have the potential to induce a num-
ber of pro-inflammatory responses as evidenced by their
ability to up-regulate chemokines, cytokines and matrix
degrading enzymes in several different cell types, includ-
ing chondrocytes [22-27,34-36]. In the present report,
we have extended these observations to include human
IVD cells, where fHA-mediated stimulation was shown
to significantly enhance the expression of pro-inflamma-
tory cytokines IL-1b, IL-6 and IL-8. Moreover, fHAs
were also found to stimulate the expression of certain
Figure 4 The effect of gene silencing on fHA-mediated IL-6 production in IVD cells. A) siRNA-mediated knockdown of genes Toll like
receptor (TLR)2, TLR4, CD44 and RHAMM was confirmed after 30 hours in intervertebral disc (IVD) cells by qRT-PCR (n = 4). In each case, gene
expression was calculated as fold change as compared to untreated cells. The use of a non-specific scrambled siRNA (siRNA (S)), confirmed
specificity of gene knockdown. B, C) Interleukin (IL)-6 protein production by Pam3CSK4- (25 ng/ml) (n = 4) (B) and lipopolysaccharide (LPS)- (25
ng/ml) (n = 3). (C) stimulated IVD cells following gene knockdown of TLR2 or TLR4 respectively, as determined by IL-6 ELISA. (D) hyaluronic acid
fragment (fHA)-treated (20 μg/ml) IVD cells following gene knockdown as determined by IL-6 ELISA (n = 4). IL-6 protein levels are represented as
a percentage of those measured for untreated cells. In all cases, analyses were performed in triplicate and values expressed as mean ± S.D.
Statistical analysis was performed using the Student’s t-test, * P <0.01.
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Figure 5 The effect of TLR2 inhibition on fHA-mediated IL-6 production in IVD cells. Interleukin (IL)-6 protein production by Pam3CSK4-
(25 ng/ml) (A) and hyaluronic acid fragment (fHA)-treated (20 μg/ml) (B) intervertebral disc (IVD) cells following antibody-mediated
neutralization of Toll like receptor (TLR)2 activity (n = 4). IL-6 protein levels are represented as a percentage of those measured for untreated
cells. In all cases, analyses were performed in triplicate and values expressed as mean ± S.D. Statistical analysis was performed using the
Student’s t-test, * P <0.05 as compared to cells treated with non-specific IgG control antibody.
Figure 6 The role of NF-B in fHA-dependent IVD cell activation. (A) Immunofluorescence staining of intervertebral disc (IVD) cells for NF-B
(p65) (green) following treatment with either hyaluronic acid fragments (fHAs) (20 μg/ml) or interleukin (IL)-1b (5 ng/ml) at selected time points.
Nuclear NF-B (p65) is indicated by arrowheads. Untreated IVD cells served as a control. Scale bar = 50 μm. (B) Western blot analysis of nuclear
extracts from untreated IVD cells or cells treated for 1 hour with either fHAs (20 μg/ml) or IL-1b (5 ng/ml). Levels of PARP1 protein served as a
loading control. (C) NF-B (p65) DNA binding activity in nuclear extracts from untreated IVD cells, or cells treated for one hour with IL-1b or
fHAs (20 μg/ml) (n = 3). In all cases, analyses were performed in triplicate and values expressed as mean ± S.D. Statistical analysis was performed
using the Student’s t-test, * P <0.01 as compared to untreated cells.
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matrix degrading enzymes, including MMP-1, MMP-3
and MMP-13, although significance was not always
attained due to the large variations between patient
samples. It is envisaged that larger population studies
may help to resolve this issue and thus allow for a more
accurate assessment of potential fHA-target genes. The
induction of such matrix degrading enzymes by fHAs
would undoubtedly contribute to IVD catabolism and
thus perpetuate the on-going destructive processes
within the actively degenerating disc. In addition to
increases in mRNA expression levels, we were also able
to detect enhanced levels of secreted IL-6 protein fol-
lowing fHA stimulation of IVD cells. This is considered
to be of particular importance when assessing the
Figure 7 Role of MAP kinases in mediating the effects of fHAs in IVD cells. Cultured intervertebral disc (IVD) cells were treated for 15
minutes with hyaluronic acid fragments (fHAs) (20 μg/ml), interleukin (IL)-1b (5 ng/ml), lipopolysaccharide (LPS) (25 ng/ml) or left untreated and
whole cell extracts harvested for Western blot analysis using antibodies specific to phosphorylated and non-phosphorylated SAPK/JNK (54/46)
(A), ERK 1/2 (44/42) (B) and p38 (C). (D, E) IVD cells were treated with fHA (20 μg/ml) alone (Control) or in combination with MAP kinase
inhibitors (10 μM) specific for p38 (SB203580), ERK 1/2 (PD98059) or SAPK/JNK (SP600125) and IL-6 (D) and matrix metalloproteinase (MMP)-3 (E)
protein levels determined by specific ELISA (n = 4). In all cases, analyses were carried out in triplicate and values expressed as mean ± S.D.
Statistical analysis was performed using Students t-test, * P <0.05, ** P <0.01 as compared to cells treated with fHAs alone (Control).
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relevance of fHAs in IVD degeneration in vivo, where
secreted cytokines are the main protagonists in driving
the pain sensation process [3,37].
The pro-inflammatory effects of LMW fHAs on
chondrocytes are generally thought to be dependent on
their interaction with TLR4 and CD44 [24,25]. In the
present report, we utilized both gene silencing and
antibody-directed inhibition approaches in an attempt
to identify potential signaling pathways responsible for
fHA-dependent IVD cell activation. Contrary to expec-
tations, functional loss of either TLR4 or CD44 did not
significantly influence fHA-induced IL-6 production in
IVD cells. Furthermore, loss-of-function studies invol-
ving RHAMM, another potential mediator of fHA-
dependent signaling, were also unable to demonstrate
any significant decreases in IL-6 secretion by fHA-
stimulated IVD cells. However, the stimulatory effects
of fHAs were significantly decreased in IVD cells in
which TLR2 expression had been effectively suppressed
following siRNA treatment. These observations were
further corroborated by studies in which TLR2 activity
was inhibited through the use of a specific neutralizing
antibody. To our knowledge, this is the first report
confirming the involvement of TLR2 in fHA-induced
cytokine production in human IVD cells.
The NF-B signal transduction pathway has previously
been implicated as a primary means through which
fHAs mediate their effects [34,38]. More specifically,
NF-B activation has been reported to mediate the sti-
mulatory effects of fHAs in chondrocytes [22,25]. In
addition to NF-B, signaling pathways involving MAP
kinases have also been shown to play a functional role
in the transduction of fHA signals [22,34]. In the pre-
sent report, we were unable to demonstrate NF-B acti-
vation in human IVD cells following treatment with
fHAs, although convincing data were obtained which
strongly implicated the MAP kinase pathway as being
an important regulator of fHA signaling. We could
demonstrate strong activation of MAP kinases ERK and
JNK in IVD cells following short-term stimulation with
fHAs, although p38 appeared to be less responsive to
the actions of fHAs. These findings may have important
ramifications in terms of identifying possible mechan-
isms through which fHAs induce both inflammatory
and catabolic responses in IVD cells. Certainly, many of
the genes up-regulated by fHAs in the current study
have previously been confirmed as MAP kinase target
genes in IVD cells [39-41]. Indeed, we were able to con-
firm activation of ERK and JNK but not p38 MAP
kinases as being necessary requirements for fHA-
mediated IL-6 production in IVD cells. Furthermore,
increases in MMP-3 protein production due to fHAs
also appeared to be dependent on JNK MAP kinase
activity. This may have significant implications when
considering therapeutic strategies for treating IVD
degeneration and inflammatory pain development, and
may, therefore, warrant further investigations into the
possible clinical benefits of using MAP kinase inhibition
for treating this debilitating disease.
Conclusions
In conclusion, the data provided in the current report pro-
vide convincing evidence that fHA-dependent stimulation
of human IVD cells is primarily regulated through TLR2-
mediated activation of the MAP kinase pathway. Further-
more, our findings offer new insights into the potential
molecular mechanisms governing IVD inflammatory pain
development in patients with IVD degeneration. Clearly,
therefore, further studies are now needed in order to con-
firm the presence and concentration of fHAs in tissue
samples, and thereby allow for an accurate assessment of
their true physiological role in IVD degeneration.
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